• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[2例乳腺癌患者的副肿瘤性视网膜病变]

[Paraneoplastic retinopathy in 2 patients with breast carcinoma].

作者信息

Huober J, Holz F G, Schmid H, Nölle B, Bellmann C, Krastel H, Wallwiener D, Bastert G

机构信息

Universitäts-Frauenklinik, Heidelberg.

出版信息

Zentralbl Gynakol. 1997;119(6):278-81.

PMID:9312964
Abstract

Paraneoplastic retinopathies are rare paraneoplastic phenomena resulting in retinal degeneration. They occur in association with different tumor types, yet most frequently encountered in small cell carcinoma of the lung. Clinical symptoms may be present before the diagnosis of the underlying malignancy. They are characterized clinically by progressive visual loss with ring scotomas, photopsia and night-blindness. An autoimmune disorder is suggested. In the sera of patients antiretinal antibodies may be detected that are sometimes reactive with the 23 kD retinal antigen recoverin, a photoreceptorprotein. We report on two patients with breast cancer who developed paraneoplastic retinopathy during the course of disease. Immunologic tests showed antiretinal antibodies that were not reactive with the 23 kD retinal antigen recoverin.

摘要

副肿瘤性视网膜病变是导致视网膜变性的罕见副肿瘤现象。它们与不同的肿瘤类型相关联,但最常见于肺癌小细胞癌。临床症状可能在潜在恶性肿瘤诊断之前出现。其临床特征为进行性视力丧失伴环形暗点、闪光感和夜盲。提示存在自身免疫性疾病。在患者血清中可检测到抗视网膜抗体,这些抗体有时与光感受器蛋白恢复蛋白(一种23 kD视网膜抗原)发生反应。我们报告了两名乳腺癌患者,她们在疾病过程中发生了副肿瘤性视网膜病变。免疫检测显示抗视网膜抗体与23 kD视网膜抗原恢复蛋白无反应。

相似文献

1
[Paraneoplastic retinopathy in 2 patients with breast carcinoma].[2例乳腺癌患者的副肿瘤性视网膜病变]
Zentralbl Gynakol. 1997;119(6):278-81.
2
[Carcinoma-associated retinopathy: a review with clinical examples].[癌相关性视网膜病变:附临床病例的综述]
Klin Monbl Augenheilkd. 2000 Jan;216(1):17-24. doi: 10.1055/s-2000-10511.
3
Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies.与抗烯醇化酶抗体相关的副肿瘤性和自身免疫性视网膜病变的临床和电生理特征
Am J Ophthalmol. 2005 May;139(5):780-94. doi: 10.1016/j.ajo.2004.12.104.
4
Role of anti-recoverin autoantibodies in cancer-associated retinopathy.抗 recoverin 自身抗体在癌症相关性视网膜病变中的作用。
Invest Ophthalmol Vis Sci. 1993 Aug;34(9):2626-33.
5
The cancer-associated retinopathy antigen is a recoverin-like protein.癌症相关性视网膜病变抗原是一种类恢复蛋白。
Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2768-72.
6
[Paraneoplastic retinal degeneration, cancer-associated retinopathy].[副肿瘤性视网膜变性,癌症相关性视网膜病变]
Ryoikibetsu Shokogun Shirizu. 2000(29 Pt 4):347-50.
7
Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo.视网膜恢复蛋白抗体在体内可诱导光感受器细胞和双极细胞凋亡。
J Autoimmun. 1998 Oct;11(5):523-33. doi: 10.1006/jaut.1998.0221.
8
Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy.恢复蛋白和热休克蛋白70在癌症相关性视网膜病变患者中被发现为自身抗原。
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):82-9.
9
[Paraneoplastic retinopathy and anti-recoverin antibodies].[副肿瘤性视网膜病变与抗恢复蛋白抗体]
Neurologia. 2002 Mar;17(3):156.
10
Clinical and immunologic aspects of cancer-associated retinopathy.癌症相关性视网膜病变的临床与免疫学方面
Am J Ophthalmol. 2004 Jun;137(6):1117-9. doi: 10.1016/j.ajo.2004.01.010.

引用本文的文献

1
Paraneoplastic neurological complications of breast cancer.乳腺癌的副肿瘤性神经并发症
Exp Hematol Oncol. 2016 Oct 24;5:29. doi: 10.1186/s40164-016-0058-x. eCollection 2015.
2
Cancer-associated retinopathy in patients with breast carcinoma.乳腺癌患者的癌症相关性视网膜病变
Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):261-5. doi: 10.1007/s00005-007-0026-6. Epub 2007 Jul 23.
3
Recoverin as a cancer-retina antigen.恢复蛋白作为一种癌视网膜抗原。
Cancer Immunol Immunother. 2007 Jan;56(1):110-6. doi: 10.1007/s00262-006-0132-z.
4
The neuropathology of paraneoplastic syndromes.副肿瘤综合征的神经病理学
Brain Pathol. 1999 Apr;9(2):251-60. doi: 10.1111/j.1750-3639.1999.tb00224.x.